LeMaitre director awarded dividend equivalents

LeMaitre Vascular director Lawrence J. Jasinski reported grants of dividend equivalent rights on existing equity awards.

Rhea-AI Filing Summary

LeMaitre Vascular director Lawrence J. Jasinski reported grants of dividend equivalent rights on existing equity awards. On 2026-06-04, he acquired several small blocks of dividend equivalent rights linked to previously granted restricted stock unit and performance share unit awards from 2023, 2024, and 2025.

Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying awards. These are compensation-related accruals with no open-market buying or selling and no cash exercise price.

Insider Trade Summary

Grant/Award: 4.0705 shares

Grant/Award 5 txns

Insider Jasinski Lawrence J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights	0.4658	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.5579	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.7595	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.8599	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	1.4274	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 21.3539 contracts (Direct)

Footnotes (5)

1. F1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
2. F2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
3. F3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
4. F4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
5. F5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Dividend equivalent rights grant: 1.4274 rights Dividend equivalent rights grant: 0.8599 rights Dividend equivalent rights grant: 0.7595 rights +2 more

5 metrics

Dividend equivalent rights grant 1.4274 rights Derivative acquisition on 2026-06-04, economic equivalent of common stock

Dividend equivalent rights grant 0.8599 rights Derivative acquisition on 2026-06-04, tied to prior award

Dividend equivalent rights grant 0.7595 rights Derivative acquisition on 2026-06-04, vesting with RSU/PSU

Dividend equivalent rights grant 0.5579 rights Derivative acquisition on 2026-06-04, compensation-related

Dividend equivalent rights grant 0.4658 rights Derivative acquisition on 2026-06-04, zero exercise price

Key Terms

Dividend Equivalent Rights, restricted stock unit award, performance share unit award, economic equivalent of one share

4 terms

Dividend Equivalent Rights financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

performance share unit award financial

"These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023"

economic equivalent of one share financial

"Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LMAT director Lawrence Jasinski report?

Lawrence J. Jasinski reported grants of dividend equivalent rights tied to prior equity awards. These rights accrued on existing restricted stock and performance share units and represent additional compensation, not open-market stock purchases or sales.

What are dividend equivalent rights in the LMAT Form 4 filing?

Dividend equivalent rights are awards that mirror dividends on underlying shares. In this LMAT filing, each right is the economic equivalent of one share of common stock and vests in step with the related stock or performance unit awards.

Were any LMAT shares bought or sold in this Form 4?

No LMAT shares were bought or sold in the open market. The Form 4 shows only grants of dividend equivalent rights with a transaction price of zero, reflecting non-cash compensation adjustments on existing equity awards.

Which LMAT awards generated the new dividend equivalent rights?

The new dividend equivalent rights accrued on restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. They vest proportionately with each corresponding award’s vesting schedule.

Does the LMAT Form 4 indicate any option exercises or tax withholding?

The LMAT Form 4 does not show option exercises or tax withholding transactions. All reported entries are acquisitions of dividend equivalent rights with no exercise price and no derivative positions remaining listed in the derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jasinski Lawrence J

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	06/04/2026		A		0.4658		(1)	(1)	Common Stock	0.4658	$0	5.0674	D
Dividend Equivalent Rights	(2)	06/04/2026		A		0.5579		(2)	(2)	Common Stock	0.5579	$0	4.8692	D
Dividend Equivalent Rights	(3)	06/04/2026		A		0.7595		(3)	(3)	Common Stock	0.7595	$0	4.2984	D
Dividend Equivalent Rights	(4)	06/04/2026		A		0.8599		(4)	(4)	Common Stock	0.8599	$0	4.4838	D
Dividend Equivalent Rights	(5)	06/04/2026		A		1.4274		(5)	(5)	Common Stock	1.4274	$0	2.6351	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)